The UK NICE has issued a final appraisal determination that the NHS should not provide lapatinib [Tyverb] News item 23 January 2013 Pages: 3 - 3
The Infectious Diseases Society of America (IDSA) has updated its guidelines for the management of candidiasis Guideline 23 January 2013 Pages: 3 - 3
NICE has recommended the use of rivaroxaban [Xarelto], a new oral anticoagulant Media release 23 January 2013 Pages: 3 - 3
Survey instrument design affects estimates of expenditure Non-clinical study 23 January 2013 Pages: 7 - 7
Pegfilgrastim worth it for preventing febrile neutropenia Clinical study 23 January 2013 Pages: 7 - 7
In a recent report, Decision Resources suggests that second-line patient share of monoamine oxidase B (MAO B) inhibitors has increased Media release 23 January 2013 Pages: 7 - 7
According to a regression analysis* based on administrative hospital data from the Swedish National Board of Health and Welfare Clinical study 23 January 2013 Pages: 8 - 8
Merging the Medicare and Medicaid databases provides a virtually complete documentation Clinical study 23 January 2013 Pages: 8 - 8
Oral cancer screening in high-risk patients cost effective Clinical study 23 January 2013 Pages: 8 - 8
Decompressive hemicraniotomy in malignant middle cerebral artery (MCA) infarction is a cost-effective intervention Clinical study 23 January 2013 Pages: 9 - 9
Epoetin-α: no QOL benefits in patients with solid tumours Clinical study 23 January 2013 Pages: 9 - 9
Alitretinoin [Toctino; Basilea Pharmaceutica] has been accepted as a treatment for severe chronic hand eczema in Scotland's NHS Media release 23 January 2013 Pages: 11 - 11
Increasing use of ranibizumab [Lucentis; Genentech, Novartis Opthalmics] will drive robust growth in the AMD* market Media release 23 January 2013 Pages: 11 - 11
The use of bevacizumab [Avastin] and cetuximab [Erbitux] will drive the colorectal cancer market to grow by almost $1 billion in 2017 Media release 23 January 2013 Pages: 11 - 11